San Diego, CA, June 4th, 2015 – Nascent Biotech, Inc., (OTC.NBIO) Nascent Biotech, Inc announced that it has begun toxicology trials on its primary asset Pritumumab, a monoclonal antibody directed against a novel antigenic target on cancer cells.
Pritumumab, a natural human IgG1 antibody, had been previously studied in brain cancer patients 20 years ago in Japan and showed no significant toxicity profile in animals or humans. Those studies were conducted using an early generation hybridoma-derived antibody. The current study at Nascent is being done using a recombinant CHO-derived Pritumumab-manufactured by Catalent Pharma Solutions. CHO cells are currently the preferred method to produce human antibodies.
Dr. Mark Glassy, Founder and Chief Science Officer commented, “We are very encouraged by the early feedback in the current toxicology trials. Using the CHO-derived pritumumab, we are attempting to show the same minimal toxicity profile displayed in previous trials, but at significantly higher doses. About half way through the current trial we are seeing similar results. This should serve Nascent well going into the Phase I-II human trials later this year.”
About Nascent Biotech, Inc:
Nascent Biotech, Inc is a clinical-stage biotech company engaged in the development of monoclonal antibodies to be used in the treatment of various cancers. Its products are not commercially available. For further information please visit our website www.nascentbiotech.com.
This news release contains “forward-looking statements” as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. These forward-looking statements generally can be identified by phrases such as its management “believes,” “expects,” “anticipates,” “foresees,” “forecasts,” “estimates” or other words or phrases of similar import. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new business opportunities and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
Nascent Biotech, Inc
Sean Carrick, President